Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Brien Rex Miller, DO
Resident, Department of Internal Medicine, Valley Hospital Medical Center, Las Vegas, NV
Resident, Department of Internal Medicine, Valley Hospital Medical Center, Las Vegas, NV
Authored Items
New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidence
Charles Jia-Haur Hu, DO
,
Jeffrey A. Bourret, PharmD
,
Chihyi Lin, DO
,
Brien Rex Miller, DO
,
Hanh Nguyen, DO
,
Quang T. Nguyen, DO, FACE, FTOS
November 2014 Vol 7, No 8
in
Original Research
Last modified: November 24, 2014